News Breaks |
|
|
| November 19, 2012 |
| 10:52 EDT |  | AMRN, GSK | Fish oil market may be bigger challenge than patents for Amarin, Forbes says Scientific publications, doctors' commentary, and prescription trends all hint that the U.S. market for prescription fish oil may be shifting dramatically, which could be a bigger problem for Amarin (AMRN) than patent protection for its Vascepa drug, according to Forbes. Use of GlaxoSmithKline's (GSK)Lovaza, an alternative treatment, has declined, the report added. Reference Link |
|
|
News For AMRN;GSK From The Last 14 Days Check below for free stories on AMRN;GSK the last two weeks. |
|
|
| June 19, 2013 |
| 08:04 EDT |  | AMRN | Amarin informed by FDA of Oct. 16 advisory committee date for sNDA for Vascepa
Subscribe for More Information |
|
| June 18, 2013 |
| 08:37 EDT |  | GSK | Drug companies turn to microchips to test medicines, WSJ reports
Subscribe for More Information |
|
| 07:13 EDT |  | GSK | Aspen in talks buy GSK's Arixtra, Fraxiparine brands
Subscribe for More Information |
|
| 07:07 EDT |  | GSK | GlaxoSmithKline receives offer for thrombosis brands from Aspen GlaxoSmithKline said it received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global. A period of exclusivity has been agreed with Aspen. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees, GSK said. "The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline," the company added. |
|
| June 12, 2013 |
| 19:54 EDT |  | GSK | GlaxoSmithKline investigates bribe claims in China, WSJ says
Subscribe for More Information |
|
| 07:16 EDT |  | GSK | GlaxoSmithKline fires head of R&D in China, WSJ says GlaxoSmithKline has fired it's head of R&D in China after finding that he had incorporated "misinterpreted" data in a paper he helped write for a journal, Nature Medicine, according to The Wall Street Journal, citing the company. Reference Link |
|
| June 11, 2013 |
| 05:56 EDT |  | AMRN | Stocks with implied volatility movement; AMRN SODA Stocks with implied volatility movement; Amarin (AMRN), SodaStream (SODA) according to IVolatility. |
|
| June 6, 2013 |
| 15:59 EDT |  | GSK | FDA votes for modified restrictions on GSK's Avandia, Reuters says
Subscribe for More Information |
|
| 15:42 EDT |  | GSK | FDA panel revote reaffirms modified restrictions for GSK's Avandia, Reuters says
|
|
| 15:26 EDT |  | GSK | FDA advisers say Glaxo Avandia vote may have been inaccurate, Bloomberg says Advisers plan to take a break to assess problem with vote tally and plan to re-vote on GSK's Avandia after break, Bloomberg says. |
| |
| 15:20 EDT |  | GSK | FDA panel votes to modify market restrictions for Avandia, Reuters says
Subscribe for More Information |
|
|
|
|
|